Saturday 17 October 2026
Export ELTX’s income statement to Excel — free account
Elicio Therapeutics, Inc.
ELTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 34.9%, free cash flow grew 8.77% and total debt rose 2.12%, each against the same quarter a year earlier.
1.56
0.22
−12.36%
Follow ELTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (774.56%) | (1,076.34%) | 817.92% | 604.57% |
+8 more TTM periods Free account |
|
| (124.36%) | (158.11%) | (146.45%) | (137.56%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(229.40%) | (435.85%) | (344.22%) | (300.15%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.96) | (2.11) | (2.42) | (2.33) | |
Free Cash Flow |
(37.69) | (38.48) | (37.05) | (38.90) | |
Capital Expenditures |
— | — | (0.10) | — | |
| Other line items | |||||
Cash ROIC |
(92.04%) | (167.40%) | (125.16%) | (113.92%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(24.00) | (27.55) | (33.29) | (41.16) | |
Operating CF/Net income |
1.00 | 0.96 | 0.93 | 0.85 | |
Depreciation/Fixed assets |
6.81 | 5.58 | 4.56 | 3.75 | |
Capex/Depreciation |
0.00 | 0.00 | (0.08) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.96) | (2.11) | (2.41) | (2.33) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
— | — | 0.00 | — |
Columns are period end dates